In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Acurx Pharmaceuticals (ACXP – Research Report). The company’s shares opened today at $1.70.
McCarthy covers the Healthcare sector, focusing on stocks such as Oncolytics Biotech, Daré Bioscience, and SELLAS Life Sciences Group. According to TipRanks, McCarthy has an average return of -30.3% and a 22.44% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Acurx Pharmaceuticals with a $13.00 average price target, implying a 664.71% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $13.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
ACXP market cap is currently $21.72M and has a P/E ratio of -1.48.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention, and Food and Drug Administration.
Read More on ACXP:
